奥希替尼联合或不联合化疗在表皮生长因子受体突变晚期非小细胞肺癌中的中枢神经系统疗效
FLAURA2 III期研究按基线中枢神经系统转移状态分析,奥希替尼联合铂类-培美曲塞相比奥希替尼单药,在可评估中枢神经系统病灶患者中中枢神经系统进展或死亡HR为0.58(95%CI 0.33-1.01),中枢神经系统客观缓解率73%对69%。结论认为联合方案改善中枢神经系统疗效,支持其作为EGFR突变晚期NSCLC一线治疗。
要点
- 基线有可测量和/或不可测量中枢神经系统病灶者纳入cFAS:联合组118/279例,单药组104/278例。
- cFAS中中枢神经系统进展或死亡HR为0.58(95%CI 0.33-1.01),无基线中枢神经系统转移者HR为0.67(95%CI 0.43-1.04)。
- cFAS中枢神经系统客观缓解率联合组73%(95%CI 64-81)对单药组69%(95%CI 59-78),完全缓解率59%对43%。
核心结论
- 奥希替尼联合铂类-培美曲塞相比奥希替尼单药显示出改善的中枢神经系统疗效,包括延迟中枢神经系统进展,与基线中枢神经系统转移状态无关。
- 这些数据支持该联合方案作为EGFR突变晚期非小细胞肺癌患者(包括中枢神经系统转移者)的新一线治疗。
研究设计与样本
- III期FLAURA2研究,患者随机分配至奥希替尼联合铂类-培美曲塞(联合组)或奥希替尼单药组,直至疾病进展或停药。
- 所有患者基线及进展时行脑扫描,基线有中枢神经系统转移者按计划评估直至进展;扫描由神经放射科中枢神经系统盲态独立中心审查(BICR)评估。
- 基于基线中枢神经系统BICR,联合组118/279例、单药组104/278例随机分配患者有≥1个可测量和/或不可测量中枢神经系统病灶,纳入中枢神经系统全分析集(cFAS)。
- 联合组40/118例、单药组38/104例有≥1个可测量靶中枢神经系统病灶,纳入事后中枢神经系统可评估缓解集(cEFR)。
主要发现
- cFAS中,中枢神经系统进展或死亡的风险比(HR)为0.58(95%CI 0.33-1.01)。
- 无基线中枢神经系统转移患者中,中枢神经系统进展或死亡的HR为0.67(95%CI 0.43-1.04)。
- cFAS中,中枢神经系统客观缓解率(ORR;95%CI)联合组为73%(64-81),单药组为69%(59-78);中枢神经系统完全缓解(CR)率联合组59%,单药组43%。
- cEFR中,中枢神经系统ORR(95%CI)联合组为88%(73-96),单药组为87%(72-96);中枢神经系统CR率联合组48%,单药组16%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status. METHODS: Patients were randomly assigned to osimertinib plus platinum-pemetrexed (combination) or osimertinib monotherapy until disease progression or discontinuation. Brain scans were performed in all patients at baseline and progression and at scheduled assessments until progression for patients with baseline CNS metastases; scans were assessed by neuroradiologist CNS blinded independent central review (BICR). RESULTS: On the basis of baseline CNS BICR, 118 of 279 (combination) and 104 of 278 (monotherapy) randomly assigned patients had ≥one measurable and/or nonmeasurable CNS lesion and were included in the CNS full analysis set (cFAS); 40 of 118 and 38 of 104 had ≥one measurable target CNS lesion and were included in the post hoc CNS evaluable-for-response set (cEFR). In the cFAS, the hazard ratio (HR) for CNS progression or death was 0.58 (95% CI, 0.33 to 1.01). In patients without baseline CNS metastases, the HR for CNS progression or death was 0.67 (95% CI, 0.43 to 1.04). In the cFAS, CNS objective response rates (ORRs; 95% CI) were 73% (combination; 64 to 81) versus 69% (monotherapy; 59 to 78); 59% versus 43% had CNS complete response (CR). In the cEFR, CNS ORRs (95% CI) were 88% (73 to 96) versus 87% (72 to 96); 48% versus 16% had CNS CR. CONCLUSION: Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.
引用
- Jänne PA, Planchard D, Kobayashi K, et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 38042525. doi:10.1200/JCO.23.02219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。